• Alkermes initiated a Phase 2 study of ALKS 7290 as an add-on to antidepressants for adults with major depressive disorder.
• The placebo-controlled trial will enroll approximately 180 adults, including those with or without excessive daytime sleepiness, for six weeks of treatment.
• The study will primarily assess safety and tolerability, with a secondary evaluation of whether the drug improves depression symptoms versus placebo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202610300700BIZWIRE_USPR_____20261030_BW521331) on October 30, 2026, and is solely responsible for the information contained therein.